Covance Softsol Ltd
F&O₹143.95▲ +0.80 (+0.56%)
COVANCE·BSE·Healthcare
Market Cap
318.78 Cr
PE Ratio
3.28
Volume
1,154
Day High - Low
144.00 - 131.20
52W High-Low
270.00 - 81.98
₹143.95▲ +0.80 (+0.56%)
Market Cap318.78 Cr
PE Ratio3.28
Volume1,154
Day High - Low144.00 - 131.20
52W High-Low270.00 - 81.98
Covance Softsol Ltd (COVANCE): company summary
Annual revenue rose 43.5% to ₹146 crore, but the latest quarter revenue fell 12.0% to ₹29 crore compared to ₹33 crore a year earlier.
Covance Softsol Ltd (COVANCE) is a micro-cap Healthcare company valued at ₹319 crore operating in Pharmaceuticals & Biotechnology on the NSE and BSE.
- Recent price move
- Covance Softsol Ltd last traded at ₹143.95, modestly up 0.56% on the day.
- Financial performance
- Annual revenue rose 43.5% to ₹146 crore, but the latest quarter revenue fell 12.0% to ₹29 crore compared to ₹33 crore a year earlier. Annual net profit surged 183.7% to ₹34 crore, while the latest quarter net profit rose 62.6% to ₹13 crore from ₹8 crore a year ago. The net profit margin widened 11.6 percentage points to 23.6%.
- Valuation multiples
- The stock trades at 3.3 times earnings, a discount to the Healthcare median of 32.0, 5.35 times book value. It yields 0.9%.
- Things to watch
- The stock is 47.0% below its 52-week high. The latest quarter revenue fell 12.0% compared to the same quarter a year earlier. The revenue has declined -85.1% annually over the last three years and -66.3% annually over the last five years.
- Where it stands
- The company's latest quarter net profit rose 62.6% to ₹13 crore, while revenue fell 12.0% to ₹29 crore. The stock is 47.0% below its 52-week high.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
6.1/10
Fair
Fair Value
Sign in to see
ROE
41.54%
Strong
P/E
3.28x
Cheap
Debt / Equity
0.00
Low
Industry
Healthcare
Pharmaceuticals & Biotechnology
Overall View
Mixed
Price performance
Day₹131.20
₹144.00
52W₹81.98
₹270.00
DocStoX take
Supported by quality (9.2) and valuation (7.2), but held back by momentum (2.6). Quality looks strong at 9.2, but that is offset by momentum at 2.6 and growth at 3.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence6.1
/10
Fair
Quality
Excellent
ROE 41.5%
Valuation
Fair
P/E 3.3×
Growth
Slow
Revenue -66.3% 5Y CAGR
Risk
Moderate
D/E 0.00
Momentum
Weak
33% of 52-week range
At a glance
Market Cap
₹319 Cr
52W High / Low
₹270 / ₹82
Dividend Yield
0.86%
Promoter Holding
71.71%
EPS (TTM)
₹43.95
Book Value
₹76.16
Key highlights
- Strong returns on equity (42%)
- Capital works hard — ROCE 31%
- Low leverage — D/E 0.00
- Profit shrinking 57% a year
- Revenue shrinking 66% a year
4 Positives3 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals & Biotechnology
Explore Covance Softsol Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Covance Softsol Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
SUN PHARMACEUTICAL IND LDIVI S LABORATORIES LTDTORRENT PHARMACEUTICALS LLAURUS LABS LIMITEDZYDUS LIFESCIENCES LTDAPOLLO HOSPITALS ENTER. LCIPLA LTDDR. REDDY S LABORATORIESAUROBINDO PHARMA LTDMANKIND PHARMA LIMITEDLUPIN LIMITEDMANIPAL HEALTH ENTERPRI L
Compare Covance Softsol Ltd with peers
Related tools & concepts
Value Covance Softsol Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing